EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

CD200/CD200R1 activation alleviates central sensitization in chronic migraine via STAT6

ZiChao Li, Dan Li, ZhenZhen Fan, HongBin Cai, ZhaoMing Ge iD

Molecular Pain · 2026

DOI: 10.1177/17448069261491583 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pain, 2026. Verfasst von ZiChao Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Lanzhou University Second Hospital, Lanzhou, Gansu, China. Hauptthemen laut MEDLINE: Migraine Disorders, STAT6 Transcription Factor, Orexin Receptors, Antigens, CD. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Lanzhou Science and Technology Plan Project, Second Hospital of Lanzhou University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Chronic migraine (CM) is characterized by central sensitization (CS), in which microglial activation plays a key role. The neuron-glia communication axis CD200/CD200R1 is a critical immunomodulatory pathway. This study investigated whether and how CD200/CD200R1 signaling modulates CS in a CM model.

Methods

A CM mouse model was established by repeated nitroglycerin (NTG) injections. Pain thresholds were assessed. Protein expression in the trigeminal nucleus caudalis (TNC) was analyzed. The role of STAT6 was examined using inhibitor AS1517499.

Results

NTG treatment induced sustained hyperalgesia and downregulated CD200 and CD200R1 expression in the TNC. Administration of the CD200R1 agonist CD200Fc reversed pain hypersensitivity, suppressed the overexpression of CGRP and c-Fos, and reduced pro-inflammatory cytokines. CD200Fc promoted STAT6 phosphorylation and increased expression of anti-inflammatory markers (Arg-1, YM-1, YM-2). Inhibition of STAT6 phosphorylation abolished the therapeutic effects of CD200Fc on pain biomarkers without altering CD200R1 expression.

Conclusion

Our findings demonstrate that enhancing the CD200/CD200R1 pathway alleviates central sensitization and pain hypersensitivity in CM, likely by promoting an anti-inflammatory microglial phenotype via STAT6 phosphorylation. The CD200/CD200R1/STAT6 axis represents a novel therapeutic target for chronic migraine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Migraine DisordersSTAT6 Transcription FactorOrexin ReceptorsAntigens, CDCentral Nervous System SensitizationAnimalsMaleChronic DiseaseMice, Inbred C57BLDisease Models, AnimalMiceHyperalgesiaSignal TransductionPhosphorylationCytokinesTrigeminal Caudal Nucleus

Stichwörter der Autor:innen

CD200CD200R1MigraineSTAT6central sensitizationmicroglia

Substanzen

STAT6 Transcription FactorOrexin ReceptorsAntigens, CDantigens, CD200Cd200r1 protein, mouseStat6 protein, mouseCytokines

Autor:innen und Institutionen

  • Department of Neurology, Lanzhou University Second Hospital, Lanzhou, Gansu, China.
  • Foot-and-Mouth Disease and Emerging Diseases Team, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou, Gansu, China.

ORCID-Profile: ZhaoMing Ge

Förderung

  • Lanzhou Science and Technology Plan Project
  • Second Hospital of Lanzhou University

Zitieren

APA

Li, Z., Li, D., Fan, Z., Cai, H., & Ge, Z. (2026). CD200/CD200R1 activation alleviates central sensitization in chronic migraine via STAT6. Molecular Pain. https://doi.org/10.1177/17448069261491583

Vancouver

Li Z, Li D, Fan Z, Cai H, Ge Z. CD200/CD200R1 activation alleviates central sensitization in chronic migraine via STAT6. Molecular Pain. 2026. doi:10.1177/17448069261491583

BibTeX
@article{Li2026,
  author = {Li, ZiChao and Li, Dan and Fan, ZhenZhen and Cai, HongBin and Ge, ZhaoMing},
  title = {CD200/CD200R1 activation alleviates central sensitization in chronic migraine via STAT6},
  journal = {Molecular Pain},
  year = {2026},
  doi = {10.1177/17448069261491583}
}
Kostenlos starten →